• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Savara receives US and Canadian patents for AeroVanc

The US Patent and Trademark Office has issued US Patent No. 9,572,774, titled "Dry Powder Vancomycin Compositions and Associated Methods," to inhaled drug developer Savara, Inc., the company said. In its statement, the company added, "This affords Savara important composition of matter protection for its AeroVanc program in the US, the largest market for the … [Read more...] about Savara receives US and Canadian patents for AeroVanc

Proveris Scientific joins IPAC-RS as an associate member

Aerosol characterization specialist Proveris Scientific has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as an associate member, the company announced. IPAC-RS now has a total of 16 member pharmaceutical companies and 5 associate members. Proveris Scientific CEO Dino Farina commented, “We are excited to join … [Read more...] about Proveris Scientific joins IPAC-RS as an associate member

AstraZeneca to collaborate with Pieris on inhaled anticalins for the treatment of respiratory disease

AstraZeneca will pay $45 million up front and up to $2.1 billion in milestone and commercial payments to Pieris Pharmaceuticals for development and commercialization rights to Pieris's inhaled anticalin therapies, Pieris said. In the near term, AstraZeneca will also provide $12.5 million for a Phase 1 trial of Pieris's lead candidate PRS-060, which is expected to … [Read more...] about AstraZeneca to collaborate with Pieris on inhaled anticalins for the treatment of respiratory disease

NIH announces funding opportunity for nasal delivery of CNS therapeutics

The US National Institutes of Health (NIH) has published two funding opportunity announcements (FOAs) related to nasal delivery of CNS therapeutics. The projects described in FOAs RFA-DA-18-006 and RFA-DA-18-007 are both supported by Small Business Technology Transfer (STTR) program Both FOAs say that their purpose is to "is to develop a nasal delivery formulation … [Read more...] about NIH announces funding opportunity for nasal delivery of CNS therapeutics

Teva launches AirDuo RespiClick and authorized generic simultaneously in US

Teva has launched both the AirDuo RespiClick fluticasone propionate/salmeterol DPI and an authorized generic version of the product in the US, the company said. The FDA approved 3 doses of AirDuo RespiClick for the treatment of asthma in patients aged 12 years and over earlier this year. The company said that it expects the majority of sales to come from the … [Read more...] about Teva launches AirDuo RespiClick and authorized generic simultaneously in US

Invion announces deal with the Cho Group

Invion has announced that Hong Kong based The Cho Group will acquire 15.03% of Invion for a total of A$656,682 through a private placement. A restructuring of Invion's board will include the addition of two members of The Cho Group. According to Invion, "The company intends to use the proceeds of the investment for working capital as it continues to market the … [Read more...] about Invion announces deal with the Cho Group

United Therapeutics to collaborate with Respira on development of RT234 DPI for the treatment of pulmonary hypertension

Respira Therapeutics has announced that United Therapeutics will fund the development of Respira's RT234 DPI for the treatment of pulmonary hypertension. United Therapeutics will get an exclusive license for the product in North America and will be the lead investor in Respira's Series B financing round. Respira will continue to develop RT234 for other … [Read more...] about United Therapeutics to collaborate with Respira on development of RT234 DPI for the treatment of pulmonary hypertension

MVP announces distribution deals for spacers in US and for Penthrox inhaler in Russia

Medical Developments International (MVP) has announced distribution deals for its compact anti-static space chambers in the US and for its Penthrox methoxyflurane inhaler in Russia. All Walmart and Kmart pharmacies in the US will carry MVP spacers. In Russia, JSC Lancet will be the distributor for Penthrox in a deal that includes milestone payments of AUD $2.3 … [Read more...] about MVP announces distribution deals for spacers in US and for Penthrox inhaler in Russia

Amneal Pharmaceuticals launches generic mometasone furoate nasal spray

Amneal Pharmaceuticals initiated shipments of its generic version of Nasonex mometasone furoate nasal spray on April 4, 2017, the company said. According to Amneal, the mometasone furoate nasal spray is its "first pharmaceutical product in spray form"; the company also markets a generic tobramycin inhalation solution. Amneal Executive VP of Sales and … [Read more...] about Amneal Pharmaceuticals launches generic mometasone furoate nasal spray

Vectura to get milestone payment after launch of Breelib nebulizer in Poland

Vectura has announced that it will receive a €5 million milestone now that Bayer AG has launched the Breelib nebulizer for Ventavis iloprost inhalation solution in Poland. Breelib is an adaptation of Vectura’s FOX handheld smart nebulizer, which Vectura acquired along with its developer, Activaero, in 2014. In addition to the initial milestone, Vectura is eligible … [Read more...] about Vectura to get milestone payment after launch of Breelib nebulizer in Poland

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 77
  • Page 78
  • Page 79
  • Page 80
  • Page 81
  • Interim pages omitted …
  • Page 153
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews